Several local companies are developing technologies that they hope could replace a painful poke with something that feels more like having Velcro against your skin for a few minutes.

Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease, plaque psoriasis, ulcerative colitis, and hidradenitis suppurativa.

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

AbbVie Inc. (NYSE:ABBV – Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors purchased 39,550 call options on the stock. This is an increase of ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis ... inhibitors including AbbVie's own blockbuster Humira (adalimumab). Meanwhile, Eli Lilly's IL ...

Over the full year, we delivered robust operational sales growth of 7% excluding the COVID-19 vaccine. With SPRAVATO ... of biosimilar entrants increase. HUMIRA's erosion curve, once faced with ...

Its key drugs include Humira for treating rheumatoid arthritis, psoriasis, Crohn's disease ... Sales for Merck's HPV vaccine Gardasil were down 11%. Hellweg says Keytruda is the star of Merck's ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...